Stocks · News reference
Why Is uniQure Stock Sinking on Tuesday?
uniQure announced long-term trial results for its Huntington's gene therapy, showing slowed disease progression at 36 and 48 months.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
RBC Capital Maintains Outperform on uniQure, Lowers Price Target to $48
UNIQURE INVESTIGATION: QURE Securities Investors Encouraged to Contact Kirby McInerney LLP About Their Rights
Law firm Kirby McInerney LLP is investigating potential securities law violations by uniQure N.V. following the release of 48-month data for AMT-130 that showed significantly reduced treatment efficacy (44% disease slowing) compared to previously reported 36-month results (75% slowing). The company had submitted an FDA application based on the stronger 36-month data. uniQure's stock price declined 37.3% on the news, falling from $39.11 to $24.51 per share.
Goldman Sachs Maintains Neutral on uniQure, Lowers Price Target to $31